EDIT 250117 25.00P (EDIT250117P25000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

EDIT250117P25000

Watchlist

17.85
0.000.00%

15min DelayClose Jan 10 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Express News | Editas Medicine Inc - to Submit at Least One Ind/Cta by 2027
Reuters13minutes ago
Express News | Editas Medicine Highlights New in Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-Year Strategic Priorities
Reuters14minutes ago
Press Release: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
Dow Jones14minutes ago
Gene Editing Stocks Drop as Intellia Announces Layoffs
Seeking AlphaJan 10 13:29 ET
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswireJan 6 09:00 ET
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?
Yahoo FinanceDec 30, 2024 15:11 ET

Comments

Jaguar8

8 minutes ago

NEWS

$Editas Medicine (EDIT.US)$
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
Monday, 13th January at 9:00 am
• Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia
• Achieved in vivo editing of liver cells in non-human primates and in vivo deliver...

Broke Trader

Dec 12, 2024 15:08

Editas Medicine Inc - Expected Costs of $55 Million to $70 Million

$Editas Medicine (EDIT.US)$

Jaguar8

Dec 12, 2024 15:01

NEWS

$Editas Medicine (EDIT.US)$
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
Thursday, 12th December at 4:00 pm
• Focus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues:
◦ Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF induction in a humanized mouse model for treatment of sickle cell...

Stock_Drift

Dec 9, 2024 14:23

$Editas Medicine (EDIT.US)$

Trytosaveabit

Oct 22, 2024 06:22

$Editas Medicine (EDIT.US)$ Editas Medicine Announced In Vivo Preclinical Proof Of Concept Data Of Hematopoietic Stem And Progenitor Cell Editing And Fetal Hemoglobin Induction In Humanized Mice Engrafted With Human Hematopoietic Stem Cells And Lacking Their Own Hematopoietic Cells
Benzinga· 2 mins ago
The Company observed high levels of editing of the HBG1/2 promoter, leveraging clinically validated upregulation strategy, utilizing a novel and Editas-proprietary targeted lipid nanoparticle (tLNP...